Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-14 5:46 pm Sale | 13G | Apogee Therapeutics Inc. APGE | RA CAPITAL MANAGEMENT L.P. | 1,961,863 3.400% | -16,038 (-0.81%) | View |
| 2024-11-14 11:16 am Purchase | 13G | Apogee Therapeutics Inc. APGE | DRIEHAUS CAPITAL MANAGEMENT LLC | 2,533,607 5.630% | 2,533,607 (New Position) | View |
| 2024-11-14 10:18 am Sale | 13G | Apogee Therapeutics Inc. APGE | Deep Track Capital LP | 1,000,000 2.220% | -1,323,456 (-56.96%) | View |
| 2024-11-12 09:50 am Purchase | 13G | Apogee Therapeutics Inc. APGE | FMR LLC | 7,502,482 16.672% | 2,483,602 (+49.49%) | View |
| 2024-11-08 2:17 pm Unchanged | 13G | Apogee Therapeutics Inc. APGE | 2,975,917 6.600% | 0 (Unchanged) | View | |
| 2024-11-04 7:59 pm Purchase | 13G | Apogee Therapeutics Inc. APGE | ACCESS INDUSTRIES MANAGEMENT LLC | 2,190,364 4.870% | 250,000 (+12.88%) | View |
| 2024-10-22 6:06 pm Purchase | 13G | Apogee Therapeutics Inc. APGE | 2,975,917 6.600% | 2,975,917 (New Position) | View | |
| 2024-10-04 10:05 am Purchase | 13G | Apogee Therapeutics Inc. APGE | WELLINGTON MANAGEMENT GROUP LLP | 4,814,400 10.700% | 4,814,400 (New Position) | View |
| 2024-04-01 5:42 pm Sale | 13D | Apogee Therapeutics Inc. APGE | Fairmount Funds Management LLC | 4,762,558 9.990% | -640,495 (-11.85%) | View |
| 2024-02-14 5:01 pm Purchase | 13G | Apogee Therapeutics Inc. APGE | RA CAPITAL MANAGEMENT L.P. | 1,977,901 5.300% | 1,977,901 (New Position) | View |
| 2024-02-14 08:35 am Sale | 13G | Apogee Therapeutics Inc. APGE | Deep Track Capital LP | 2,323,456 6.250% | -700,000 (-23.15%) | View |
| 2024-02-09 08:35 am Purchase | 13G | Apogee Therapeutics Inc. APGE | FMR LLC | 5,018,880 13.496% | 570,979 (+12.84%) | View |
| 2024-01-31 4:30 pm Purchase | 13D | Apogee Therapeutics Inc. APGE | Fairmount Funds Management LLC | 5,403,053 9.990% | 1,496,851 (+38.32%) | View |
| 2023-11-03 4:01 pm Purchase | 13G | Apogee Therapeutics Inc. APGE | ACCESS INDUSTRIES MANAGEMENT LLC | 1,940,364 5.220% | 1,940,364 (New Position) | View |
| 2023-08-10 08:19 am Purchase | 13G | Apogee Therapeutics Inc. APGE | FMR LLC | 4,447,901 12.094% | 4,447,901 (New Position) | View |
| 2023-07-28 4:15 pm Purchase | 13D | Apogee Therapeutics Inc. APGE | Venrock Healthcare Capital Partners III L.P. | 3,887,478 9.990% | 3,887,478 (New Position) | View |
| 2023-07-24 4:05 pm Purchase | 13G | Apogee Therapeutics Inc. APGE | Deep Track Capital LP | 3,023,456 8.870% | 3,023,456 (New Position) | View |
| 2023-07-21 4:31 pm Purchase | 13D | Apogee Therapeutics Inc. APGE | Fairmount Funds Management LLC | 3,906,202 9.990% | 3,906,202 (New Position) | View |